Novel method for distinguishing between metastatic and benign pheochromocytoma
Rebecca Ireland
This article has no abstract so we have provided the first paragraph of the full text.
Metastasis of pheochromocytoma (a rare, catecholamine-producing tumor of chromaffin cells) occurs in up to 36% of patients, with a 50% mortality rate at 5 years. Currently, there are no markers that can reliably distinguish between benign and malignant pheochromocytoma, or predict progression of benign tumors; and there is no cure for metastatic disease. Furthermore, progression can take as long as 20 years in some patients. Brouwers et al. employed BIOINFORMATICS to study profiles of low-molecular-mass proteins in sera from 67 pheochromocytoma patients (34 metastatic and 33 benign cases), to determine whether they could be used as biomarkers for tumor behavior.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.